April 18, 2023 – The FDA on Tuesday approved a second bivalent COVID-19 booster for Americans at higher risk, in the hopes of increasing the public’s protection and encouraging more people to get the vaccine, which targets both the original strain of the SARS-CoV-2 virus and two Omicron variants.
The Moderna and Pfizer-BioNTech monovalent (single-strain) mRNA COVID vaccines will no longer be available, as the agency withdrew emergency use authorizations for both.
The FDA recommended an additional bivalent booster for:
- People age 65 or older who have received one bivalent dose, as long as it is 4 months after that initial shot
- Most unvaccinated…